Current Clinical Trials

We aim to list an easily understandable description of any MDS clinical trials currently opened to recruitment in the UK.

Patients will be able to read up on the details of these trials and use this information to discuss with their consultants or nurses. If you'd like more information about what a clinical trial is and how it is conducted, please go to this section or download our Clinical Trials factsheet.

Not all patients can be enrolled in drug trials - as not every patient will fit the necessary inclusion criteria, which need to be followed very strictly. However, if a particular clinical trial drug is considered an option by the haematologist, it is sometimes possible to obtain the drug outside the trial, on the basis of compassionate use.

MDS Clinical Trials

FT-2102: Clinical Trial Open to Recruitment

FT-2102: Clinical Trial Open to Recruitment
  1. SUB-TYPE OF MDS: Patients with Acute Myeloid Leukaemia or Myelodysplastic Syndrome with an IDH1 R132 mutation
  2. SEVERITY OF MDS: Intermediate, high risk or very high risk MDS as defined by the World Health Organization (WHO) criteria or Revised International Prognostic Scoring System (IPSS-R)
  3. NAME OF DRUG: FT-2102
Read full story

LI-1 – Clinical Trial Open to Recruitment

LI-1 – Clinical Trial Open to Recruitment
  1. SUB-TYPE OF MDS: MDS with 10% or more bone marrow blasts and also acute myeloid leukaemia
  2. SEVERITY OF MDS: Intermediate –2 or High Risk
  3. NAME OF DRUG: AC220 (Quizartinib), Ganetespib, Tosedostat, Selinexor, Lenalidomide and other novel therapies that will become available throughout the course of the study. These are all target treatments that block various pathways in the proliferation or growth of leukaemia cells.
Read full story

AML 19 – Clinical Trial Open to Recruitment

AML 19 – Clinical Trial Open to Recruitment
  1. SUB-TYPE OF MDS: MDS with 10% bone marrow blasts OR more; also acute myeloid leukaemia
  2. SEVERITY OF MDS: Intermediate – 2 or High Risk
  3. NAME OF DRUG: Mylotarg, CPX-351 (a novel drug which combines two anti-cancer drugs – cytarabine and daunorubicin in a new formulation)
Read full story

AML 18 – Clinical Trial Open to Recruitment

AML 18 – Clinical Trial Open to Recruitment
  1. SUB-TYPE OF MDS: MDS with 10% or more bone marrow blasts; also acute myeloid leukaemia
  2. SEVERITY OF MDS: Intermediate – 2 or High Risk
  3. NAME OF DRUG: Mylotarg, AC220 (a novel drug that blocks the action of a gene – FLT3, which is important in the growth of blood cells
Read full story
Free donations by shopping